The highest 5-year OS rate among therapies for advanced melanoma was observed with combined anti-CTLA-4 and anti-PD-1 checkpoint inhibition, which is most strongly associated with the highest incidence of immune-related adverse events [176,181]. The gene discussed is CTLA4; the disease is melanoma.